NCT05584722Recruiting
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
Source: ClinicalTrials.gov · Last updated 10 Mar 2026
Brief summary (registry, in English)
Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with known genetic defects, provide a unique opportunity to determine the features of susceptibility and resilience to PAH. This proposal will fundamentally overturn the prevailing understanding of PAH by creating molecularly-driven signatures of susceptibility and resilience, provide novel insight into disease severity, and potentially identify new therapeutic targets. Funding Source - FDA OOPD
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 14 Oct 2022
- Start date
- 1 Nov 2022
- Primary completion date
- 31 Aug 2026
- Lead sponsor
- Vanderbilt University Medical Center
- NCT number
- NCT05584722
What you commit to
- Study type: Observational
- Planned participants: 150
- From 1 Nov 2022 to the primary completion date, 31 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Requirement of \> 2 diuretic adjustment in the prior three months.
Other illness
- Prohibited from normal activity due to wheelchair bound status, bed bound status, reliance on a cane/walker, activity-limiting angina, activity-limiting osteoarthritis, or other condition that limits activity.
- Functional class IV heart failure
Other
- Pregnancy
- Diagnosis of PAH etiology other than idiopathic, heritable
Who the study is looking for
- Children and Adults, aged 15 - 80
- Diagnosed with idiopathic or heritable, pulmonary arterial hypertension (PAH), defined according to standard criteria
- Unaffected Mutation Carriers: Healthy participants with a known BMPR2 gene mutation and normal pulmonary pressure and RV function on echo
- Healthy Controls: Healthy individuals without cardiopulmonary disease.
- WHO functional class I-III
- Stable PAH-specific medication regimen for three months prior to enrollment. Subjects with only a single diuretic adjustment in the prior three months will be included. Adjustments in IV prostacyclin for side effect management are allowed.
Age in the registry: 15 years to 80 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Vanderbilt University Medical Center Coordinator of this site? Confirm its status | Nashville | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.